Bristol-Myers Squibb

Explore the latest insights on Bristol-Myers Squibb and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Bristol-Myers Squibb’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.Explore the latest insights on Bristol-Myers Squibb and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Bristol-Myers Squibb's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Novo Nordisk Opens Its Next Chapter With 'Lasting Health Starts Now' Rebrand and 'The Novo Way' Culture – Single 'Novo' Name Signals a Faster, Consumer‑Driven Era
Company

Novo Nordisk Opens Its Next Chapter With ‘Lasting Health Starts Now’ Rebrand and ‘The Novo Way’ Culture – Single ‘Novo’ Name Signals a Faster, Consumer‑Driven Era

Novo Nordisk (NYSE: NVO) today unveiled a corporate rebrand centred on "Lasting Health Starts Now" and the single "Novo" name, together with an updated corporate culture, "The Novo Way", designed…

Sichuan Biokin's HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen

Sichuan Biokin’s HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen

Henlius' Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China's Bone Health Market

Henlius’ Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China’s Bone Health Market

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyLegal / IP

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

CompanyDrug

Bristol-Myers Squibb Secures FDA Approval for Iberdomide Combination in Multiple Myeloma – First‑Ever Nod Based on MRD‑Negative Response Data

Others

AstraZeneca and Bristol-Myers Squibb Explore $400B Mega-Merger to Reshape Global Pharma Landscape

BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis – First Selective TYK2 Inhibitor Expands China Indications
CompanyDrug

BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis – First Selective TYK2 Inhibitor Expands China Indications

CompanyDrug

SystImmune and Bristol Myers Squibb’s Dual-Targeted ADC Izalontamabbrengitecan Shows Significant Survival Benefit in Two Phase III Trials

BMS' Camzyos Receives FDA Priority Review for Adolescent Obstructive HCM Treatment
CompanyDrug

BMS’ Camzyos Receives FDA Priority Review for Adolescent Obstructive HCM Treatment

BMS Secures EC Approval for Opdivo-AVD Combination in Advanced Classical Hodgkin Lymphoma
CompanyDrug

BMS Secures EC Approval for Opdivo-AVD Combination in Advanced Classical Hodgkin Lymphoma

CompanyDrug

Bristol-Myers Squibb’s Mezigdomide-Kd Combination Shows 52% Risk Reduction in Relapsed Multiple Myeloma in Phase 3 SUCCESSOR-2 Trial

Show More